¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå ¼ºÀå°ú µ¿Çâ
±Þ¼º±â ¿ø°ÝÀÇ·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â 633¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â »çÀÌ 15.23%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÇ·á ºÎ¹®ÀÇ ±â¼ú °³¹ß, ÀÇ·á¿¡ ´ëÇÑ Áï°¢ÀûÀÎ Á¢±Ù¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ƯÈ÷ °³¹ßµµ»ó±¹ÀÇ Àü¹®ÀÇ ºÎÁ·Àº ±Þ¼º±â ÀÇ·á ºÐ¾ß¿¡¼ ¿ø°ÝÀÇ·áÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
COVID-19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ÀÇ·á ½Ã½ºÅÛÀº ´Ù¾çÇÑ µµÀü¿¡ Á÷¸éÇÏ°Ô µÇ¾ú½À´Ï´Ù. »çȸÀû °Å¸®µÎ±â ½Ã´ë¿¡ Áö¼ÓÀûÀÎ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇØ¾ß ÇÏ´Â »óȲ¿¡¼ ´Ù¾çÇÑ ±â¼úÀÌ ±¹°¡¸¦ ÃÊ¿ùÇÏ¿© ºü¸£°Ô äÅõǰí ÀÖÀ¸¸ç, ±Þ¼º±â ÀÇ·á ºÐ¾ß¿¡¼ ¿ø°ÝÀÇ·áÀÇ º¸±ÞÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ ¸ÞµðÄÉ¾î ¹× ¸ÞµðÄÉÀÌµå ¼ºñ½º ¼¾ÅÍ(CMS)´Â 2020³â ÃÊ COVID-19°¡ °øÁߺ¸°Ç ºñ»ó»çÅ·Π¼±Æ÷µÈ Á÷ÈĺÎÅÍ º´¿øÀ̳ª ÀÇ·á½Ã¼³°ú °°Àº °ø°øÀå¼Ò¿¡¼ »ç¶÷µéÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ³ëÃâÀ» ÁÙÀÌ¸é¼ Áø·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇѽÃÀû ¸éÁ¦¸¦ ÅëÇØ ¿ø°ÝÀÇ·á ¼ºñ½º Àû¿ë ¹üÀ§¸¦ È®´ëÇß½À´Ï´Ù. ¸¦ ÅëÇØ ¿ø°ÝÀÇ·á ¼ºñ½º Àû¿ë ¹üÀ§¸¦ È®´ëÇß½À´Ï´Ù.
¶ÇÇÑ ¼¼°èº¸°Ç±â±¸(WHO)¿Í ±¹Á¦Àü±âÅë½Å¿¬ÇÕ(ITU)Àº ±¹Á¦ÀûÀÎ Â÷¿ø¿¡¼ ÀÌ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ¿ø°ÝÀÇ·á ¼ºñ½º À̿뿡 ´ëÇÑ º¸ÆíÀûÀÎ ±âÁØÀ» ¸¶·ÃÇϱâ À§ÇØ Çù·ÂÇß½À´Ï´Ù. ÀÌ °¡À̵å¶óÀÎÀº ¿ø°ÝÀÇ·á Ç÷§ÆûÀÌ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¿ø°ÝÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ ¿ø°ÝÀÇ·á Ç÷§ÆûÀÌ ÃæÁ·ÇØ¾ß ÇÒ ±â¼úÀû ±âÁØÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.
2021³â 12¿ù, ¾î¼¾¼Ç ÅØ»ç½ºÀÇ 5°³ ½Ã¼³Àº ȯÀÚ¿¡°Ô ¿ø°Ý ½Å°æÇÐ ¼ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ ¹Ì±¹ÀÇ ÁÖ¿ä ´Ù°ú¸ñ ¿ø°ÝÀÇ·á ±×·ì°ú Çù·ÂÇß½À´Ï´Ù. ÀÌ Á¦È޴ Ư¼ö ½Å°æÇÐ Ä¡·á¿¡ ´ëÇÑ 24/7 Á¢±Ù¼ºÀ» º¸ÀåÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ÀÇ»ç, °£È£»ç ¹× ±âŸ Àü¹®°¡°¡ Çʿ信 µû¶ó ½Å°æ°ú ÀÇ»ç¿Í °íÈÁú È»ó »ó´ãÀ» ÅëÇØ ÇöÀå ½Å°æ°ú Ä¡·á¸¦ °ÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- äÆÃ°ú È»ó ȸÀǸ¦ ÅëÇØ ÀÇ·á Àü¹®°¡¿¡°Ô ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°í, Ä¡·á¸¦ À§ÇÑ ±ä ´ë±â ½Ã°£°ú À̵¿ ½Ã°£À» ÁÙÀÏ ¼ö Àֱ⠶§¹®¿¡ 2024³â ½ÃÀå ¸ÅÃâ Á¡À¯À²Àº ÀÇ»ç ´ë ȯÀÚ ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.
- ¿ø°Ý Á¤½ÅÀÇ·á ºÎ¹®Àº 2025-2030³â »çÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®Àº ÀüÅëÀûÀÎ ´ë¸é Á¤½Å°ú ½Ã¼³À» ´ëüÇÒ ¼ö ÀÖ´Â ´õ ³ªÀº ´ë¾ÈÀÌ µÉ ¼ö Àֱ⠶§¹®¿¡ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È 15.4%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̴ ƯÈ÷ ½ÅÈï±¹¿¡¼ Àü¹®Àǰ¡ ºÎÁ·Çϰí ÀÇ·á ¼ºñ½º Á¢±Ù¼º Çâ»ó¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
- ºÏ¹Ì ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀåÀº 2024³â ¸ÅÃâ Á¡À¯À² 42.1%·Î ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ´Â À¯¸®ÇÑ »óȯ ±¸Á¶¿Í ¿ø°ÝÀÇ·á ¼ºñ½º ÀÌ¿ëÀÌ °¡´ÉÇϱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 1¿ù ¹Ì±¹ ¿ø°ÝÀÇ·áÇùȸ(ATA)¿Í µðÁöÅÐÀÇ·áÇùȸ(DiMe)´Â °¡»ó ÀǷḦ À§ÇÑ »õ·Î¿î ÇÁ·Î±×·¥ÀÎ 'IMPACT'¸¦ ½ÃÀÛÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ±Þ¼º±â ¿ø°ÝÀÇ·á : ½ÃÀå ºÐ¼® Åø
- »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTLE ºÐ¼®
Á¦4Àå ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå ºÎ¹® ºÐ¼®, Á¦°ø ¹æ¹ýº°, 2018-2030³â(100¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- Á¦°ø ¹æ¹ý ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå, Á¦°ø ¹æ¹ýº°, 2018-2030³â
- ÀÓ»óÀÇ ´ë ȯÀÚ
- ÀÓ»óÀÇ ´ë ȯÀÚ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ÀÓ»óÀÇ ´ë ÀÓ»óÀÇ
- ÀÓ»óÀÇ ´ë ÀÓ»óÀÇ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦5Àå ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå ºÎ¹® ºÐ¼®, ¿ëµµº°, 2018-2030³â(100¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå, ¿ëµµº°, 2018-2030³â
- ¿ø°Ý¹æ»ç¼±Áø´Ü
- ¿ø°Ý¹æ»ç¼±Áø´Ü ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿ø°ÝÁ¤½Å°ú
- ¿ø°ÝÁ¤½Å°ú ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿ø°ÝICU
- ¿ø°ÝICU ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿ø°Ý½Å°æÇÐ
- ¿ø°Ý½Å°æÇÐ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿ø°Ý½ÅÀåÇÐ
- ¿ø°Ý½ÅÀåÇÐ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦6Àå ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â(100¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- º´¿ø°ú Ŭ¸®´Ð
- º´¿ø°ú Ŭ¸®´Ð ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦7Àå ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå ºÎ¹® ºÐ¼®, Áö¿ªº°, 2018-2030³â(100¸¸ ´Þ·¯)
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- Áö¿ª ½ÃÀå ÇöȲ
- ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå Á¡À¯À²(Áö¿ªº°, 2024³â°ú 2030³â)
- ºÏ¹Ì
- ºÏ¹ÌÀÇ ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- À¯·´ÀÇ ±Þ¼º±â ¿ø°ÝÀÇ·á ½ÃÀå, 2018-2030³â
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷ ºÐ·ù
- ±â¾÷ °³¿ä
- ScienceSoft USA Corporation
- AMN Healthcare
- Orbit Health GmbH
- US Acute Care Solutions, LLC
- Access TeleCare, LLC
- SynergenX
- Eagle Telemedicine
- Enghouse Video(Vidyo, Inc.)
- RelyMD
ksm 24.11.25
Acute Care Telemedicine Market Growth & Trends:
The global acute care telemedicine market size is expected to reach USD 63.31 billion in 2030 and is projected to grow at a CAGR of 15.23% from 2025 to 2030. Technological development in the healthcare sector, increasing demand for immediate access to medical care, and shortage of specialty physicians especially in developing countries are some factors driving telemedicine growth in an acute care setting.
The COVID-19 pandemic caused the healthcare system to encounter various challenges. The swift adoption of various technologies across countries, driven by the necessity to provide continued medical care in the era of social distancing, has increased the penetration of telemedicine in acute care. In addition, the Centers for Medicare & Medicaid Services (CMS) increased the coverage of telehealth services through temporary waivers soon after the declaration of COVID-19 as a public health emergency in early 2020 to make it convenient for people to receive medical care while reducing their exposure to the virus in public settings such as hospitals and health care facilities.
Furthermore, the World Health Organization and the International Telecommunication Union (ITU) collaborated to produce a universal standard for the usage of telehealth services to address the problem on an international scale. This guideline describes the technological criteria that a telehealth platform must fulfill to deliver accessible telehealth services.
In December 2021, Five Ascension Texas facilities collaborated with the nation's major multispecialty telemedicine group to offer teleneurology services to their patients. The collaboration was intended to ensure 24/7 access to special neurology care. It will also strengthen on-site neurology treatment by offering doctors, nurses, and other professionals high-definition video consultations with neurologists on demand.
Acute Care Telemedicine Market Report Highlights:
- Based on delivery, the clinician-to-patient segment dominated the market with the largest revenue share in 2024 as it provides easy access to medical professionals through chat or video conferencing and reduces long waiting and travel times to get treatment.
- The telepsychiatry segment is anticipated to witness the fastest growth from 2025 to 2030. The sector is witnessing significant growth as it holds the potential to become a better option to traditional in-person psychiatric facilities.
- Based on the end-use, the hospitals and clinics segment dominated the market with the largest revenue share in 2024 and is anticipated to witness the fastest growth with a CAGR of 15.4% over the forecast period. This is owing to the shortage of specialist physicians, especially in developing countries, and increased demand for better healthcare access among the people.
- North America acute care telemedicine market dominated the global market with a revenue share of 42.1% in 2024. Due to a favorable reimbursement structure and the availability of telemedicine services. For instance, In January 2021, The American Telemedicine Association (ATA) and the Digital Medicine Society (DiMe) launched "IMPACT" a new program for virtual healthcare.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment scope
- 1.1.2. Regional scope
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.7. Research Assumptions
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Delivery outlook
- 2.2.2. Application outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Acute Care Telemedicine Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Acute Care Telemedicine: Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTLE Analysis
Chapter 4. Acute Care Telemedicine Market Segment Analysis, By Delivery, 2018 - 2030 (USD Million)
- 4.1. Definition and Scope
- 4.2. Delivery Market Share Analysis, 2024 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Acute Care Telemedicine Market, by Delivery, 2018 to 2030
- 4.5. Clinician-to-Patient
- 4.5.1. Clinician-to-Patient market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Clinician-to-Clinician
- 4.6.1. Clinician-to-Clinician market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Acute Care Telemedicine Market Segment Analysis, By Application, 2018 - 2030 (USD Million)
- 5.1. Definition and Scope
- 5.2. Application Market Share Analysis, 2024 & 2030
- 5.3. Segment Dashboard
- 5.4. Global Acute Care Telemedicine Market, by Application, 2018 to 2030
- 5.5. Teleradiology
- 5.5.1. Teleradiology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Telepsychiatry
- 5.6.1. Telepsychiatry market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Tele-ICU
- 5.7.1. Tele-ICU market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.8. Teleneurology
- 5.8.1. Teleneurology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.9. Telenephrology
- 5.9.1. Telenephrology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.10. Others
- 5.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Acute Care Telemedicine Market Segment Analysis, By End Use, 2018 - 2030 (USD Million)
- 6.1. Definition and Scope
- 6.2. End Use Market Share Analysis, 2024 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Acute Care Telemedicine Market, by End Use, 2018 to 2030
- 6.5. Hospitals and Clinics
- 6.5.1. Hospitals and Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Acute Care Telemedicine Market Segment Analysis, By Region, 2018 - 2030 (USD Million)
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Regional Market Snapshot
- 7.4. Acute Care Telemedicine Market Share by Region, 2024 & 2030:
- 7.5. North America
- 7.5.1. North America acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.5.2. U.S.
- 7.5.2.1. U.S. acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.5.3. Canada
- 7.5.3.1. Canada acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Mexico acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6. Europe
- 7.6.1. Europe acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.2. UK
- 7.6.2.1. UK acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.3. Germany
- 7.6.3.1. Germany acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.4. France
- 7.6.4.1. France acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.5. Italy
- 7.6.5.1. Italy acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.6. Spain
- 7.6.6.1. Spain acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.7. Norway
- 7.6.7.1. Norway acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.8. Sweden
- 7.6.8.1. Sweden acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.6.9. Denmark
- 7.6.9.1. Denmark acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Japan acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. China acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. India acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Australia acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. South Korea acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Thailand acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Brazil acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.8.2. Argentina
- 7.8.2.1. Argentina acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. South Africa acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Saudi Arabia acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. UAE acute care telemedicine market, 2018 - 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Kuwait acute care telemedicine market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Profiles
- 8.3.1. ScienceSoft USA Corporation
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Product benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. AMN Healthcare
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Product benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Orbit Health GmbH
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. U.S. Acute Care Solutions, LLC
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Access TeleCare, LLC
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. SynergenX
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Eagle Telemedicine
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Enghouse Video (Vidyo, Inc.)
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. RelyMD
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives